JP2006525223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006525223A5 JP2006525223A5 JP2004542219A JP2004542219A JP2006525223A5 JP 2006525223 A5 JP2006525223 A5 JP 2006525223A5 JP 2004542219 A JP2004542219 A JP 2004542219A JP 2004542219 A JP2004542219 A JP 2004542219A JP 2006525223 A5 JP2006525223 A5 JP 2006525223A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- sequence identity
- residue
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200201546 | 2002-10-11 | ||
| DKPA200201587 | 2002-10-16 | ||
| US41922502P | 2002-10-17 | 2002-10-17 | |
| PCT/DK2003/000691 WO2004032953A1 (en) | 2002-10-11 | 2003-10-13 | Treatment of allergic conditions by use of il 21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006525223A JP2006525223A (ja) | 2006-11-09 |
| JP2006525223A5 true JP2006525223A5 (enExample) | 2006-12-21 |
Family
ID=32096538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004542219A Withdrawn JP2006525223A (ja) | 2002-10-11 | 2003-10-13 | Ｉｌ２１の使用によるアレルギー症状の治療 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1553970A1 (enExample) |
| JP (1) | JP2006525223A (enExample) |
| AU (1) | AU2003273758A1 (enExample) |
| BR (1) | BR0315134A (enExample) |
| CA (1) | CA2501807A1 (enExample) |
| MX (1) | MXPA05003729A (enExample) |
| PL (1) | PL376118A1 (enExample) |
| WO (1) | WO2004032953A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2507817C (en) | 2002-12-13 | 2014-04-22 | Zymogenetics, Inc. | Il-21 production in prokaryotic hosts |
| AU2005244942A1 (en) * | 2004-05-19 | 2005-12-01 | Wyeth | Modulation of immunoglobulin production and atopic disorders |
| EP1937838B1 (en) * | 2005-09-22 | 2011-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of using il-21 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2329274A1 (en) * | 1998-05-29 | 1999-12-02 | Steven M. Ruben | Interleukin-21 |
| DK1165791T3 (da) * | 1999-03-09 | 2008-02-11 | Zymogenetics Inc | Humant cytokin som zalpha-receptor-ligand og anvendelse deraf |
| EP1806404B1 (en) * | 2000-07-27 | 2010-08-18 | Wyeth LLC | Use of IL-10 receptor beta antagonistic antibodies for inhibiting IL-TIF/IL-21 induction of acute phase proteins |
| EP1432431B1 (en) * | 2001-10-04 | 2017-05-10 | Genetics Institute LLC | Methods and compositions for modulating interleukin-21 activity |
| AU2003230834A1 (en) * | 2002-04-09 | 2003-10-27 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of il-21 and modulation of il-21-mediated t cell responses |
-
2003
- 2003-10-13 WO PCT/DK2003/000691 patent/WO2004032953A1/en not_active Ceased
- 2003-10-13 MX MXPA05003729A patent/MXPA05003729A/es not_active Application Discontinuation
- 2003-10-13 JP JP2004542219A patent/JP2006525223A/ja not_active Withdrawn
- 2003-10-13 EP EP03757715A patent/EP1553970A1/en not_active Withdrawn
- 2003-10-13 BR BR0315134-4A patent/BR0315134A/pt not_active Application Discontinuation
- 2003-10-13 PL PL03376118A patent/PL376118A1/xx unknown
- 2003-10-13 AU AU2003273758A patent/AU2003273758A1/en not_active Abandoned
- 2003-10-13 CA CA002501807A patent/CA2501807A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009268467A5 (enExample) | ||
| EP2267022A3 (en) | KDR peptides and vaccines comprising the same | |
| MX2019015502A (es) | L-asparaginasa modificada. | |
| JP2010529860A5 (enExample) | ||
| NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| NZ628987A (en) | Extended recombinant polypeptides and compositions comprising same | |
| JP2010065037A5 (enExample) | ||
| JP2017221201A5 (enExample) | ||
| WO2007076162A3 (en) | Antimicrobial cathelicidin peptides | |
| JP2014529399A5 (enExample) | ||
| WO2008052173A3 (en) | Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use | |
| JP2006506942A5 (enExample) | ||
| WO2009025116A1 (ja) | Cdh3ペプチド及びこれを含む薬剤 | |
| JP2019534884A5 (enExample) | ||
| WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections | |
| JP2011521661A5 (enExample) | ||
| EP2481748A3 (en) | Foxp3 peptide vaccine | |
| WO2010103515A3 (en) | Compositions and methods for prevention and treatment of neurodegenerative diseases | |
| JP2006503088A5 (enExample) | ||
| JP2006525223A5 (enExample) | ||
| JP2008531463A5 (enExample) | ||
| JP2012507278A5 (enExample) | ||
| JP2018529625A5 (enExample) | ||
| JP2017525357A5 (enExample) | ||
| JP2005535281A5 (enExample) |